Global Presence

As one of the first Chinese biopharmaceutical enterprises to enter the international market, 3SBio launched its export business through Chinese export corporations in 2004. We subsequently expanded our partnerships with local distributors in the Middle East, the Commonwealth of Independent States, Latin America, and Asian countries, thereby steadily building a global commercial network.

Currently, our main products sold overseas include flagship varieties such as TPIAO, EPIAO, Yisaipu, Cipterbin, and SEPO. Our international footprint continues to expand, with marketing approvals obtained for 58 product specifications in over 40 countries, and more than 40 additional product specifications under review by over 13 relevant pharmaceutical regulatory authorities. In 2025, our overseas revenue grew by 32.8% year over year, with order volume hitting a record high.

Our manufacturing sites have secured over 17 authoritative international GMP certifications from the U.S. FDA, the EU, and PIC/S member countries including Brazil, Turkey, Ukraine, and Thailand. Meanwhile, 3SBio is actively adapting to the evolving global pharmaceutical regulatory landscape and exploring localized production and local joint venture projects in core regional markets, aiming to move beyond product exports toward a deeper level of industrial globalization.

With a solid foothold in China and a global footprint, 3SBio will continue to expand access to innovative biologics in more countries and regions, while steadily advancing toward its vision to evolve into a world-leading biopharmaceutical enterprise.